These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27665849)

  • 1. Influences of CYP2D6
    Pei Q; Huang L; Huang J; Gu JK; Kuang Y; Zuo XC; Ding JJ; Tan HY; Guo CX; Liu SK; Yang GP
    Acta Pharmacol Sin; 2016 Nov; 37(11):1499-1508. PubMed ID: 27665849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
    Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
    J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
    van der Weide K; van der Weide J
    J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
    Volpi S; Potkin SG; Malhotra AK; Licamele L; Lavedan C
    J Clin Psychiatry; 2009 Jun; 70(6):801-9. PubMed ID: 19573479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.
    Chen B; Xu Y; Jiang T; Feng R; Sun J; Zhang W; Yang W; Li J; Adeniyi O; Chen H
    J Clin Pharm Ther; 2013 Dec; 38(6):504-11. PubMed ID: 23981149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
    Locatelli I; Kastelic M; Koprivsek J; Kores-Plesnicar B; Mrhar A; Dolzan V; Grabnar I
    Eur J Pharm Sci; 2010 Oct; 41(2):289-98. PubMed ID: 20599499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
    Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
    Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic analysis of tramadol and
    Lee J; Yoo HD; Bae JW; Lee S; Shin KH
    Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
    Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
    Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
    Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
    Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.